Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Regulatory News (POLX)

  • There is currently no data for POLX

Director Dealing

22 Jan 2020 16:03

RNS Number : 6364A
Polarean Imaging PLC
22 January 2020
 

Polarean Imaging Plc 

("Polarean" or the "Company")

 

Director Dealing

 

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that yesterday it was notified that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 337,574 Ordinary Shares of £0.00037 ("Ordinary Shares") at an average price of 29.6 pence per share on 20 January 2020.

Following this transaction, Dr Allis now holds a beneficial interest in 1,877,574 Ordinary Shares, representing approximately 1.64 per cent. of the Company's issued share capital.

 

Enquiries: 

 

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com 

Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

Richard Morgan, Chairman 

 

 

 

SP Angel Corporate Finance LLP 

Tel: +44 (0)20 3470 0470  

David Hignell / Soltan Tagiev (Corporate Finance) 

 

Vadim Alexandre / Rob Rees (Corporate Broking)

 

 

Walbrook PR 

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com 

Anna Dunphy / Paul McManus 

Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Dr Jonathan Allis

2.

Reason for the notification

a)

Position/status:

Non-Executive Director

b)

Initial notification/Amendment:

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Polarean Imaging Plc

b)

LEI:

213800DGR2BHXJ36OL37

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

 

Ordinary shares of £0.00037

GB00BF3DT583

b)

Nature of the transaction:

Purchase of shares

c)

Price(s) and volume(s):

 

Price(s)

Volume(s)

29.9 pence

33,444

29.9 pence

33,444

29.9 pence

33,444

29.5 pence

33,898

29.5 pence

67,796

29.5 pence

50,847

29.5 pence

50,803

29.5 pence

33,898

 

d)

Aggregated information:

Aggregated volume:

Price:

 

Price(s)

Volume(s)

29.6 pence

337,574

 

 

 

e)

Date of the transaction:

20 January 2020

f)

Place of the transaction:

AIM, London Stock Exchange

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGZGZMVZGGGZM
Date   Source Headline
11th Oct 20197:01 amRNSPolarean notes statement from Amphion Innovations
9th Oct 20197:00 amRNSHolding(s) in Company
3rd Oct 20197:00 amRNSPolarean notes statement from Amphion Innovations
25th Sep 20197:00 amRNSPolarean notes statement from Amphion Innovations
24th Sep 20197:00 amRNSHalf-year Report
10th Sep 20195:15 pmRNSPolarean notes statement from Amphion Innovations
10th Sep 20197:00 amRNSNew System Installation
9th Aug 20194:14 pmRNSStatement on Amphion Innovations
5th Aug 20197:00 amRNSPhase III Clinical Trials update
31st Jul 201910:04 amRNSTotal Voting Rights
30th Jul 20193:18 pmRNSHolding(s) in Company
30th Jul 20192:25 pmRNSHolding(s) in Company
29th Jul 20195:31 pmRNSHolding(s) in Company
25th Jul 20193:31 pmRNSResult of AGM
24th Jul 20192:45 pmRNSExercise of Warrants
22nd Jul 201910:00 amRNSPlacing to raise £2.1 million
11th Jul 20197:00 amRNSNew System Order
27th Jun 20197:00 amRNSFinal Results
13th Jun 20195:02 pmRNSInvestor Symposium presentations available online
11th Jun 20197:00 amRNSPhase III Clinical Trials - Update
5th Jun 20197:00 amRNSNew System Order
23rd May 20193:26 pmRNSGrant of Share Options
23rd May 20197:00 amRNSLondon Investor Symposium
21st May 20197:00 amRNS3rd tranche of $3m pediatric study grant confirmed
13th May 20197:00 amRNSClinical trial update
30th Apr 20197:00 amRNSTotal Voting Rights
29th Apr 20197:00 amRNSAppointment of Chief Financial Officer
2nd Apr 20197:00 amRNSExercise of Warrants
1st Apr 20197:00 amRNSAmphion Innovations - Pledge of Polarean shares
15th Feb 20197:00 amRNSNew System Order
24th Jan 20197:00 amRNSAppointment of Nominated Adviser and Broker
21st Jan 20193:36 pmRNSHolding(s) in Company
3rd Jan 20197:00 amRNSHolding(s) in Company
28th Dec 20182:52 pmRNSResult of General Meeting and Total Voting Rights
11th Dec 20187:05 amRNSInvestment in Polarean & Loan Facility Repayment
11th Dec 20187:00 amRNSConditional Fundraise to raise US$4 million
13th Nov 20187:00 amRNSLicencing Agreement with Duke University
6th Nov 20187:00 amRNSCompany update
5th Nov 20187:00 amRNSNominated Adviser Status
3rd Oct 20187:00 amRNSDelivery of Xenon Polariser
23rd Aug 20187:00 amRNSFIRST PATIENT IN PHASE III FDA CLINICAL TRIAL
22nd Aug 20187:00 amRNSHalf-year Report
27th Jul 20187:00 amRNSCompany update
18th Jul 20182:28 pmRNSResult of AGM
17th Jul 20182:49 pmRNSHolding(s) in Company
10th Jul 20183:22 pmRNSResult of Placing
9th Jul 20182:41 pmRNSProposed Placing to raise a minimum of £0.78m
21st Jun 201810:12 amRNSHolding(s) in Company
19th Jun 20184:40 pmRNSSecond Price Monitoring Extn
19th Jun 20184:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.